Merck & Co., Inc. Deferred State and Local Income Tax Expense (Benefit)
Merck & Co., Inc. (MRK) reported Deferred State and Local Income Tax Expense (Benefit) of -$3.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-24
- Merck & Co., Inc. deferred state and local income tax expense (benefit) for fiscal 2025 was -$3.00M, a 121.43% decline from fiscal 2024.
- Merck & Co., Inc. deferred state and local income tax expense (benefit) for fiscal 2024 was $14.00M.
- Merck & Co., Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was -$107.00M.
- Merck & Co., Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$129.00M, a 637.50% decline from fiscal 2021.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$3.00M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $14.00M 10-K · filed 2026-02-24 | |
| 2023-12-31 | -$107.00M 10-K · filed 2026-02-24 | |
| 2022-12-31 | -$129.00M 10-K · filed 2025-02-25 | |
| 2021-12-31 | $24.00M 10-K · filed 2024-02-26 | |
| 2020-12-31 | -$25.00M 10-K · filed 2023-02-24 | -$23.00M 10-K · filed 2021-02-25 |
| 2019-12-31 | -$4.00M 10-K · filed 2022-02-25 | $14.00M 10-K · filed 2020-02-26 |
| 2018-12-31 | -$43.00M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $262.00M 10-K · filed 2020-02-26 | |
| 2016-12-31 | -$41.00M 10-K · filed 2019-02-27 | |
| 2015-12-31 | -$49.00M 10-K · filed 2018-02-27 | |
| 2014-12-31 | -$237.00M 10-K · filed 2017-02-28 | |
| 2013-12-31 | $38.00M 10-K · filed 2016-02-26 | |
| 2012-12-31 | $243.00M 10-K · filed 2015-02-27 | |
| 2011-12-31 | -$270.00M 10-K · filed 2014-02-27 | |
| 2010-12-31 | -$79.00M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $163.00M 10-K · filed 2012-02-28 | |
| 2008-12-31 | $55.00M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |